Evidence map›Paper›PMID 34391897›Full record

ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2022

Interleukin-5 receptor alpha (CD125) expression on human blood and lung neutrophils.

Monica G Lawrence, W Gerald Teague, Xin Feng, Caitlin Welch, Elaine Etter, Julie Negri, Marthajoy Spano, Kristin Wavell, Thomas Braciale, John W Steinke and 1 more

Open access · greenAbstract read
In one paragraph

Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Further evidence of a type 2 inflammatory signature in chronic obstructive pulmonary disease or emphysema.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023
    Article
  6. Frontiers in pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Monica G LawrenceDepartment of Medicine, University of Virginia, Charlottesville, Virginia; Child Health Research Center, Department of Pediatrics, University of Virginia, Charlottesville, Virginia. Electronic address: ml4nz@virginia.edu.
W Gerald TeagueChild Health Research Center, Department of Pediatrics, University of Virginia, Charlottesville, Virginia.
Xin FengDepartment of Otorhinolaryngology, Qilu Hospital of Shandong University, Shandong, People's Republic of China; NHC Key Laboratory of Otorhinolaryngology, Shandong University, Jinan, Shandong, People's Republic of China.
Caitlin WelchDepartment of Medicine, University of Virginia, Charlottesville, Virginia.
Elaine EtterDepartment of Medicine, University of Virginia, Charlottesville, Virginia.
Julie NegriDepartment of Medicine, University of Virginia, Charlottesville, Virginia.
Marthajoy SpanoDepartment of Pathology, University of Virginia, Charlottesville, Virginia.
Kristin WavellChild Health Research Center, Department of Pediatrics, University of Virginia, Charlottesville, Virginia.
Thomas BracialeDepartment of Pathology, University of Virginia, Charlottesville, Virginia; Department of Microbiology, University of Virginia, Charlottesville, Virginia.
John W SteinkeDepartment of Medicine, University of Virginia, Charlottesville, Virginia; Genentech, Charlottesville, Virginia.
Larry BorishDepartment of Medicine, University of Virginia, Charlottesville, Virginia; Department of Microbiology, University of Virginia, Charlottesville, Virginia.
University of Virginia · USShandong University · CN

Funding

An Evaluation of Treatment with Omalizumab to Improve the Asthmatic Response to aU01AI100799 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYMANN, PETER W, PLATTS-MILLS, THOMAS A. · 2012 to 2015
$5.3M
Clinical response to rhinovirus challenge in human asthmaticsU01AI123337 · NIAID · UNIVERSITY OF VIRGINIA · PI BORISH, LARRY C · 2016 to 2020
$3.6M
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)UG1HL139126 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2017 to 2022
$2.4M
Lung rhinovirus (RV) infection identifies pre-school children with type 2 inflammation at risk for the development of asthmaR21AI151496 · NIAID · UNIVERSITY OF VIRGINIA · PI BORISH, LARRY C, TEAGUE, WILLIAM GERALD · 2020 to 2021
$444k
Clinical immune response to rhinovirus challenge in human asthmaticsR56AI120055 · NIAID · UNIVERSITY OF VIRGINIA · PI BORISH, LARRY C · 2015 to 2015
$386k
NHLBI NIH HHS UG1 HL139126NIAID NIH HHS R21 AI151496NIAID NIH HHS R56 AI120055NIAID NIH HHS U01 AI100799NIAID NIH HHS U01 AI123337
6 · The paper itself

Abstract

backgroundOur previous studies revealed the presence of interleukin-5 (IL-5) receptor alpha chain (IL-5Rα, CD125) on neutrophils in a murine model of influenza and in the lung fluid of children with severe asthma.

objectiveTo further evaluate the functional characteristics and effects of clinical factors and inflammatory variables on neutrophil surface IL-5Rα abundance in lung fluid and blood.

methodsIL-5Rα expression was quantified by flow cytometry performed on purified neutrophils from blood and bronchoalveolar lavage fluid samples obtained from healthy controls and individuals with asthma. Expression was further confirmed by immunohistochemistry. Functional signaling through the IL-5Rα was evaluated by measurement of IL-5-inducible modulation of neutrophil surface CD62L and IL-5Rα expression.

resultsIL-5Rα was consistently present but at a variable magnitude on blood and lung neutrophils. Expression on lung neutrophils was significantly higher than that on blood cells (p"?>P < .001) where their expression was higher in the presence of airway pathogens, especially with respiratory viruses. Increased receptor expression occurred in response to the translocation of preformed receptors from intracellular stores. Receptors were functional as revealed by IL-5-mediated down-regulation of CD62L and the feed-forward up-regulation of reception expression.

conclusionIn addition to the expression on eosinophils and basophils, the IL-5Rα is consistently and abundantly expressed on the surface of blood and especially air space neutrophils. These observations support the concept that some of the efficacy of IL-5/IL-5R-targeting biologics observed in asthma may reflect their ability to target neutrophilic air space inflammation.

Indexed as

AsthmaNeutrophilsHumansInterleukin-5Interleukin-5 Receptor alpha SubunitLungInterleukin-5Interleukin-5 Receptor alpha Subunit

Identifiers

PMID34391897
PMCPMC8671196
OpenAlexW3195036098

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.